Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angiogene Pharmaceuticals Ltd.

http://www.angiogene.co.uk

Latest From Angiogene Pharmaceuticals Ltd.

MediciNova's Ibudilast Shows Potential In Progressive MS

The only approved treatment for primary progressive MS is Roche's Ocrevus but there is a possible competitor on the horizon following promising Phase II data which showed that ibudilast slowed brain shrinkage by nearly half.

Neurology Clinical Trials

Deals Shaping The Medical Industry, July-August 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

OXiGENE licenses Angiogene's know-how to support carcinoid syndrome PhII work

OXiGENE, a clinical-stage company based in South San Francisco, has gained worldwide rights to the intellectual property and know-how relating to Oxford, UK-based Angiogene Pharmaceuticals' vascular disrupting agent programme for neuroendocrine cancers, focused mainly on carcinoid syndrome.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register